zolgensma 2x1013vg ml infuzní roztok - rezultati pretrage

Ujedinjeni Arapski Emirati - engleski - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

zolgensma® 2 × 10^13 vector genomes/ml infusion

alphamed drug store united states of america - 1 kit (5.5 ml or 8.3 ml single use vial x 2 to 14) - infusion - 2 × 10^13 vector genomes/ml - nervous system-modifying neuromuscular transmission

Saudijska Arabija - engleski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

zolgensma suspension for injection

novartis europharm limited, ireland - onasemnogene abeparvovec - suspension for injection - 2000000000000 vg/ml,

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

solensia solution for injection for cats

zoetis australia pty ltd - frunevetmab - parenteral liquid/solution/suspension - frunevetmab active 7.0 mg - immunotherapy

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

zolgensma

novartis new zealand ltd - onasemnogene abeparvovec 20tvg/ml (tvg = tera vector genomes; equivalent to 2 x 10^13 vector genomes per ml); onasemnogene abeparvovec 20tvg/ml (tvg = tera vector genomes; equivalent to 2 x 10^13 vector genomes per ml) - solution for infusion - active: onasemnogene abeparvovec 20tvg/ml (tvg = tera vector genomes; equivalent to 2 x 10^13 vector genomes per ml) excipient: hydrochloric acid magnesium chloride poloxamer 188 sodium chloride trometamol water for injection active: onasemnogene abeparvovec 20tvg/ml (tvg = tera vector genomes; equivalent to 2 x 10^13 vector genomes per ml) excipient: hydrochloric acid magnesium chloride poloxamer 188 sodium chloride trometamol water for injection - zolgensma is an adeno-associated virus (aav) vector-based gene therapy indicated for the treatment of paediatric patients with spinal muscular atrophy (sma) with a bi allelic mutation in the survival motor neuron 1 (smn1) gene.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

zolgensma

novartis new zealand ltd - onasemnogene abeparvovec 20tvg/ml (tvg = tera vector genomes; equivalent to 2 x 10^13 vector genomes per ml) - solution for infusion - active: onasemnogene abeparvovec 20tvg/ml (tvg = tera vector genomes; equivalent to 2 x 10^13 vector genomes per ml) excipient: hydrochloric acid magnesium chloride poloxamer 188 sodium chloride trometamol water for injection - zolgensma is an adeno-associated virus (aav) vector-based gene therapy indicated for the treatment of paediatric patients with spinal muscular atrophy (sma) with a bi allelic mutation in the survival motor neuron 1 (smn1) gene.